SPOTLIGHT: GPC finds positive satraplatin data


Researchers at GPC Biotech say that they've discovered that a group of patients previously treated with Taxotere demonstrated a positive trend toward survival when treated with the experimental prostate cancer drug satraplatin. That data has persuaded the company to continue research on the therapy, which failed a pivotal late-stage trial. Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.